Cybin Investor Relations Material
Latest events
Fireside Chat
Cybin
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cybin Inc
Access all reports
Cybin Inc. is a clinical-stage biopharmaceutical company dedicated to developing psychedelic-based therapeutics. The company focuses on creating treatments for mental health conditions through innovative drug discovery platforms, drug delivery systems, and formulation approaches. Cybin is developing a range of proprietary psychedelic molecules, including CYB003, a deuterated psilocybin analog for major depressive disorder, and CYB004, a deuterated DMT molecule for generalized anxiety disorder. These efforts are part of Cybin's broader mission to address unmet needs in mental healthcare with novel therapeutic options. The company is headquartered in Toronto, Canada, and its shares are listed on the NYSE.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
CYBN
Country
🇺🇸 United States